A
3.42
0.13 (3.95%)
| Penutupan Terdahulu | 3.29 |
| Buka | 3.29 |
| Jumlah Dagangan | 623,592 |
| Purata Dagangan (3B) | 863,238 |
| Modal Pasaran | 648,062,656 |
| Harga / Jualan (P/S) | 88.00 |
| Harga / Buku (P/B) | 5.83 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Feb 2025 - 3 Mar 2025 |
| Margin Operasi (TTM) | -1,304.78% |
| EPS Cair (TTM) | -0.430 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -71.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 6.32% |
| Nisbah Semasa (MRQ) | 7.02 |
| Aliran Tunai Operasi (OCF TTM) | -71.83 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -39.81 M |
| Pulangan Atas Aset (ROA TTM) | -32.83% |
| Pulangan Atas Ekuiti (ROE TTM) | -67.81% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Arbutus Biopharma Corporation | Menurun | Menurun |
AISkor Stockmoo
-0.6
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.63 |
|
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 22.22% |
| % Dimiliki oleh Institusi | 53.84% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Whitefort Capital Management, Lp | 30 Sep 2024 | 12,867,967 |
| Two Seas Capital Lp | 30 Sep 2024 | 8,387,388 |
| Blackbarn Capital Partners Lp | 30 Sep 2024 | 2,070,900 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 5.00 (Chardan Capital, 46.20%) | Beli |
| 5.00 (HC Wainwright & Co., 46.20%) | Beli | |
| Median | 5.00 (46.20%) | |
| Purata | 5.00 (46.20%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 3.48 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Chardan Capital | 20 Nov 2024 | 5.00 (46.20%) | Beli | 3.44 |
| 06 Nov 2024 | 4.50 (31.58%) | Beli | 3.92 | |
| HC Wainwright & Co. | 18 Nov 2024 | 5.00 (46.20%) | Beli | 3.52 |
| 07 Nov 2024 | 5.00 (46.20%) | Beli | 3.73 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |